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The present study. In this issue of the Journal, Fitz-
Gibbon et at. (1) describe a long-term study in which 
consecutive postoperative angiographic examinations were 
performed on 741 saphenous vein grafts in 222 patients. All 
grafts were evaluated early (mean 0.96 months), at 1 year 
(mean 12.84 months) and >6.5 (mean 9.6) years after oper-
ation; the majority of these grafts (565) were also examined 
5 years postoperatively. At the late examination, 237 grafts 
were restudied an average of7.5 years, 403 an average of 10 
years and 101 ~ 11.5 years after operation. The subjects were 
mainly military personnel, all male, ranging in age from 31 to 
67 years (mean 45.7). 
Graft occlusion rates in these consecutive studies in-
creased from 8% early, to 13% at 1 year and to 20% 5 years 
after operation. Late occlusion rates were 41 % at 7.5 years, 
41 % at 10 years and 45% after 11.5 years. Early after 
operation no patent graft showed irregularities of outline; 
however, 7% showed a stenosis reducing the graft lumen to 
a diameter <50% of the grafted artery diameter. As shown in 
previous studies from our institution (2-4), most of these 
narrowings were at the distal anastomosis between the graft 
and the coronary artery and were presumably related to 
faulty surgical technique. At 1 year, 8% of patent grafts had 
at least some irregularities of outline. Six percent of them 
(that is, 0.5% of patent grafts) showed a narrowing that 
reduced the graft lumen by >50%. Although FitzGibbon et 
at. attribute this narrowing to graft atherosclerosis, we doubt 
that this was the case. Solymoss et al. (5) from our institution 
and other investigators (6) have not seen histologic evidence 
of graft atherosclerosis during the 1st 12 months after 
operation. In our experience these segmental narrowings are 
secondary to localized fibrointimal hyperplasia of vein grafts 
(2-4). By 5 years, 38% of patent grafts had irregularities of 
outline and were considered to have developed atheroscle-
rosis. However, only 14% of them, that is, 5% of patent 
grafts, showed a >50% reduction of the graft lumen. Finally, 
at 10 years, 75% of patent grafts showed angiographic 
evidence of atherosclerosis. Thirty-five percent of them, 
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(26% of all patent grafts) showed a >50% reduction of the 
graft lumen. 
Clinical significance of study. Graft patency rates and the 
incidence of luminal irregularities or narrowings on the shaft 
of the graft or at the coronary anastomosis have been studied 
extensively at contrast angiography within the 1st 5 years 
after coronary artery bypass grafting (2,7-9). Overall, ap-
proximately 80% of saphenous vein grafts remain patent 5 
years after operation. This includes a 5% to 10% incidence of 
graft closure within the 1st month, a 10% to 15% incidence at 
1 year and a low incidence (5% to 10%) between 1 and 5 
years after operation. Localized stenoses on the graft shaft 
or at the coronary anastomosis occur in 5% to 10% of cases 
early and relatively less often at 1 year. These narrowings, 
when they reduce the lumen of the graft by ~50%, fre-
quently lead to occlusion at subsequent examinations (2-4). 
In contrast, few data are available on graft patency after 
5 years, particularly on the rate and extent of progression of 
graft atherosclerosis between 5 and 10 years after operation 
and on the influence of these atherosclerotic changes on late 
graft occlusion (3,10-12). The present data by FitzGibbon et 
at. (1) support and confirm previous data from the Cleveland 
Clinic (12) and from our institution (3). 
Previous studies. In 1983 Campeau et at. (3) from our 
institution reported sequential angiographic examinations at 
2 weeks, 1 year, 5 to 7 years and 10 to 12 years after 
aortocoronary saphenous vein bypass grafting in 147 grafts 
from 82 unselected patients. Graft occlusion rates in these 
consecutive angiographic examinations were as follows: 
3.4% at 2 to 3 weeks, 10% at 6 to 18 months, 19% at 5 to 7 
years and 37% at 10 to 12 years after operation. Between 5 
and 7 years, angiographic evidence of atherosclerosis was 
present in 16% of patent grafts. One third of these athero-
sclerotic grafts (5% of patent grafts) showed narrowings that 
reduced the graft lumen by ~50%. In contrast, between 10 
and 12 years after operation, 46% of patent grafts had 
angiographic evidence of atherosclerosis and 70% of them 
(32% of patent grafts) showed narrowings that reduced the 
graft lumen by ~50%. Graft closure was 2.5 times more 
frequent during the 6 to 11 year interval as compared with 
the 1 to 6 year interval. Attrition was more prevalent in 
grafts with focal narrowings and with atherosclerosis at the 
previous examination. 
Lytle et al. (12) from the Cleveland Clinic performed two 
successive postoperative angiograms in 501 patients and 786 
saphenous vein grafts. All grafts were studied at ~5 years 
(range 1 to 59 months, mean 15 months) and at >5 years 
(range 60 to 147 months, mean 88 months) after operation. 
An average of 7.3 years after operation, 36% of the grafts 
were occluded, 18% were stenotic (45% with graft lumen 
reduction of ::::50%) and 45% were widely patent. 
Thus, despite obvious differences in study design and 
patient selection, the findings from these three groups are in 
relatively close agreement. Between 35% and 40% of vein 
grafts are occluded between 7 and 12 years (average 10) after 
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coronary artery bypass grafting. As shown by our group and 
by FitzGibbon et al. (1), an additional 25% to 30% of these 
grafts show "significant" (;?:50% luminal reduction) athero-
sclerotic narrowings. Overall, 60% to 70% of vein grafts can 
be considered to be functionally impaired an average of 10 
years after operation. 
The 7.5 year phenomenon. FitzGibbon et al. (I) observed 
that the greatest incidence of graft occlusion and of severe 
graft atherosclerosis occurred at 7.5 years after operation. 
This was followed by a more or less constant incidence of 
obstruction in grafts studied 10 and;?: 11.5 years after oper-
ation. Graft occlusion increased from 20% at 5 years to 41 % 
at 7.5 years. The number of grafts with ;?:50% luminal 
narrowings increased from 5% at 5 years to 31 % at 7.5 years. 
Our group (3) previously showed a marked acceleration of 
graft atherosclerosis and occlusion between 5 and 10 years 
after operation. FitzGibbon et al. (I) observed that primarily 
unscheduled symptomatic patients were restudied during 
this period. Indeed, this time interval corresponds to the 
period when severe symptoms often recur after coronary 
artery bypass grafting. It also coincides with a period of 
increased surgical mortality in the recent randomized trials 
of coronary bypass surgery (13-15). 
Histologic studies (5) have shown a different aspect of the 
progression of graft atherosclerosis. Atherosclerosis was 
almost always absent in vein grafts examined during the 1 st 
12 months, and only 11% of grafts showed evidence of 
atherosclerosis between 1 and 3 years after operation. How-
ever, atherosclerosis was documented in 66% of grafts 
between 3 and 6 years and this incidence remained relatively 
constant between 6 and 13 years after operation. 
Thus, the development of vein graft atherosclerosis 
reaches a peak between 3 and 6 years after operation. 
However, the disease usually does not progress to the 
symptomatic stage until several years later. 
Diseased graft prognosis. FitzGibbon et al. (I) observed 
that diseased grafts became more diseased at subsequent 
examinations and that occlusion occurred in many. This 
phenomenon was well documented some years ago by our 
group (2,3) and by other investigators (12). For example, 
about half of the grafts with constricted anastomoses early 
after operation in our series were occluded at 1 year and half 
of the remaining grafts also occluded during the subsequent 
10 years. Likewise, localized narrowings on the graft trunk 
at the 1 year examination often led to late graft occlusion, 
particularly when they reduced the graft lumen by ;?:50%. 
Finally, the presence of atherosclerosis between 5 and 7 
years after operation also strongly influenced late graft 
patency (3). Closure was noted between 10 and 12 years after 
operation in 43% of grafts with such lesions as compared 
with only 20% in unchanged grafts or in grafts with diffuse 
narrowing. However, the course of diffuse intimal fibromus-
cular hyperplasia noted between 6 and 18 months after 
operation constituted a notable exception in our patients. 
Even moderate to severe diffuse intimal hyperplasia showed 
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no significant progression after the 1st year and this was not 
a determinant of late graft closure (3). 
FitzGibbon et al. (I) also point out that absence of disease 
has little prognostic significance because diseased and oc-
cluded grafts were often generated by those with healthy 
appearances at earlier examinations. This is not at all sur-
prising. Except for variable degrees of diffuse intimal hyper-
plasia, most patent grafts have a normal angiographic ap-
pearance 1 year after operation. Thus, grafts developing 
atherosclerosis at 5 years were usually considered healthy at 
1 year and grafts showing late atherosclerotic changes or late 
occlusions were often considered healthy at 1 and 5 years 
after operation. 
The future. In contrast to the saphenous vein, the inter-
nal thoracic artery remains free of atherosclerosis late after 
operation (10,16). Patency rates of almost 90% have been 
reported at 10 years. In recent years the internal thoracic 
artery has become the conduit of choice for coronary artery 
bypass grafting. However, as emphasized by FitzGibbon et 
al. (I), routine use of the right internal thoracic and right 
gastroepiploic arteries is often not practical and vein grafts 
are still needed in the majority of patients with multivessel 
disease. Therefore, we must actively pursue our quest for 
effective methods of improving their long-term patency. 
Continued efforts to minimize endothelial and graft injury 
during saphenous vein harvesting by the use of meticulous 
surgical techniques is essential. Antiplatelet agents have 
been shown to effectively reduce early graft thrombosis in 
recent clinical trials (17,18). Their use should be mandatory 
during the 1st year after operation. The development and 
progression of atherosclerosis beyond the 1 st year after 
operation may be related to the usual coronary risk factors 
and an adequate control of these factors is important. 
However, these measures have been adopted to a variable 
extent for a number of years and, as suggested by Fitz-
Gibbon et al. (1), they appear to have had a limited impact on 
long-term vein graft patency. 
Future efforts should probably concentrate on three ma-
jor areas: prevention of the development of atherosclerosis, 
prevention of the progression of atherosclerosis and preven-
tion of late graft thrombosis. 
Although this is still controversial, intimal fibromuscular 
hyperplasia may be a precursor of atherosclerosis in vein 
grafts. Because they do not adequately inhibit platelet adhe-
sion to the exposed subendothelium, currently prescribed 
antiplatelet agents do not prevent the intimal hyperplasia of 
vein grafts. More potent platelet inhibitors, as well as 
inhibitors of smooth muscle cell proliferation, may be effec-
tive in preventing this lesion in the future. Some of these 
drugs are currently under investigation for the prevention of 
restenosis after coronary angioplasty. 
Data from our institution (19) have shown that serum 
lipids may playa major role in the progression of atheroscle-
rosis in vein grafts. A beneficial effect of a lipid-lowering 
regimen on progression and regression of atherosclerotic 
lesions was demonstrated recently (20,21) in both vein grafts 
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and native coronary arteries. Ongoing trials are attempting 
to confirm and extend these observations. Obviously, the 
long-term efficacy of these drug regimens will have to be 
documented. 
Finally, late occlusion of vein grafts is almost regularly 
associated with thrombosis at the site of atherosclerotic 
lesions and, in that respect, the mechanism of late vein graft 
occlusion may be similar to that of coronary occlusion (5). 
The efficacy of antiplatelet agents and of oral anticoagulants 
in preventing late graft thrombosis has not been adequately 
documented. In addition, newer, more potent orally admin-
istered antithrombotic agents may become available in the 
future. 
The long-term fate of aortocoronary saphenous vein 
bypass grafts provides a human model of rapid onset and 
progression of atherosclerosis and of late thrombosis. Effec-
tive measures modifying the atherosclerotic process in this 
model would undoubtedly be applicable to other vascular 
territories. 
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